Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, ...

Author Shawn Peters blends clarity and rigor to make data structures and algorithms accessible to all learners. COLORADO, CO, UNITED STATES, January 2, 2026 /EINPresswire.com/ — Vibrant Publishers ...

Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

AI can help design AI systems: automating architecture choices, discovering algorithms, and optimizing hardware ...

新年伊始，MIT CSAIL 的一纸论文在学术圈引发了不小的讨论。Alex L． Zhang 、 Tim Kraska 与 Omar Khattab 三位研究者在 arXiv 上发布了一篇题为《Recursive Language ...

研究人员提出的递归语言模型（Recursive Language Models, RLMs）通过引入Python交互环境，让模型学会写代码去分块读取、检索并递归调用自身处理信息，成功在千万级Token的超长文本任务中实现了性能与成本的双重突破。